222 related articles for article (PubMed ID: 24982070)
1. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.
Jacobsson S; Golparian D; Alm RA; Huband M; Mueller J; Jensen JS; Ohnishi M; Unemo M
Antimicrob Agents Chemother; 2014 Sep; 58(9):5585-8. PubMed ID: 24982070
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
Su XH; Wang BX; Le WJ; Liu YR; Wan C; Li S; Alm RA; Mueller JP; Rice PA
Antimicrob Agents Chemother; 2016 Jan; 60(1):621-3. PubMed ID: 26482313
[TBL] [Abstract][Full Text] [Related]
4. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
Unemo M; Ringlander J; Wiggins C; Fredlund H; Jacobsson S; Cole M
Antimicrob Agents Chemother; 2015 Sep; 59(9):5220-5. PubMed ID: 26077246
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
Huband MD; Bradford PA; Otterson LG; Basarab GS; Kutschke AC; Giacobbe RA; Patey SA; Alm RA; Johnstone MR; Potter ME; Miller PF; Mueller JP
Antimicrob Agents Chemother; 2015 Jan; 59(1):467-74. PubMed ID: 25385112
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.
Alm RA; Lahiri SD; Kutschke A; Otterson LG; McLaughlin RE; Whiteaker JD; Lewis LA; Su X; Huband MD; Gardner H; Mueller JP
Antimicrob Agents Chemother; 2015 Mar; 59(3):1478-86. PubMed ID: 25534723
[TBL] [Abstract][Full Text] [Related]
7. In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.
Papp JR; Lawrence K; Sharpe S; Mueller J; Kirkcaldy RD
Int J Antimicrob Agents; 2016 Sep; 48(3):328-30. PubMed ID: 27499432
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
Kohlhoff SA; Huband MD; Hammerschlag MR
Antimicrob Agents Chemother; 2014 Dec; 58(12):7595-6. PubMed ID: 25288086
[TBL] [Abstract][Full Text] [Related]
9. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Basarab GS; Kern GH; McNulty J; Mueller JP; Lawrence K; Vishwanathan K; Alm RA; Barvian K; Doig P; Galullo V; Gardner H; Gowravaram M; Huband M; Kimzey A; Morningstar M; Kutschke A; Lahiri SD; Perros M; Singh R; Schuck VJ; Tommasi R; Walkup G; Newman JV
Sci Rep; 2015 Jul; 5():11827. PubMed ID: 26168713
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.
Biedenbach DJ; Huband MD; Hackel M; de Jonge BL; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2015 Oct; 59(10):6053-63. PubMed ID: 26195518
[TBL] [Abstract][Full Text] [Related]
11. High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance.
Jeverica S; Golparian D; Hanzelka B; Fowlie AJ; Matičič M; Unemo M
J Antimicrob Chemother; 2014 Jul; 69(7):1866-72. PubMed ID: 24651828
[TBL] [Abstract][Full Text] [Related]
12. In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae.
Foerster S; Drusano G; Golparian D; Neely M; Piddock LJV; Alirol E; Unemo M
J Antimicrob Chemother; 2019 Dec; 74(12):3521-3529. PubMed ID: 31730160
[TBL] [Abstract][Full Text] [Related]
13.
Masuko A; Takata I; Fujita K; Okumura H; Ushiyama F; Amada H; Sugiyama H
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558293
[TBL] [Abstract][Full Text] [Related]
14. Management of
Pisano L; Giovannuzzi S; Supuran CT
Expert Opin Ther Pat; 2024 Jun; 34(6):511-524. PubMed ID: 38856987
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains.
Jacobsson S; Golparian D; Phan LT; Ohnishi M; Fredlund H; Or YS; Unemo M
J Antimicrob Chemother; 2015 Jan; 70(1):173-7. PubMed ID: 25182063
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates.
Hamasuna R; Ohnishi M; Matsumoto M; Okumura R; Unemo M; Matsumoto T
Microb Drug Resist; 2018; 24(1):30-34. PubMed ID: 28581359
[TBL] [Abstract][Full Text] [Related]
17.
Jacobsson S; Paukner S; Golparian D; Jensen JS; Unemo M
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893785
[TBL] [Abstract][Full Text] [Related]
18. A Novel Oral GyrB/ParE Dual Binding Inhibitor Effective against Multidrug-Resistant
Park S; Russo R; Westfall L; Shrestha R; Zimmerman M; Dartois V; Kurepina N; Kreiswirth B; Singleton E; Li SG; Mittal N; Ahn YM; Bilotta J; Connolly KL; Jerse AE; Freundlich JS; Perlin DS
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0041422. PubMed ID: 35972242
[TBL] [Abstract][Full Text] [Related]
19. In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.
Waites KB; Crabb DM; Duffy LB; Huband MD
Antimicrob Agents Chemother; 2015; 59(6):3627-9. PubMed ID: 25824220
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea?
Jacobsson S; Mason C; Khan N; Meo P; Unemo M
J Antimicrob Chemother; 2019 Jun; 74(6):1591-1594. PubMed ID: 30778550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
